Last 48 quarters of trend data · Healthcare · Medical Devices
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -110.31 | — | 15.24 | — | 120.73 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1.58 | 2.15 | 1.51 | 1.66 | 1.15 | 1.22 | 1.35 | 2.05 | — | 2.35 | 3.06 | 2.30 | 1.93 | 1.64 | 2.15 | 2.77 | 2.73 | 2.16 | 2.05 | 2.47 | 3.61 |
| — | +76.6% | +11.9% | -19.3% | — | -48.2% | -56.0% | -10.9% | — | +43.1% | +42.0% | -17.0% | -29.4% | -23.8% | +5.1% | +12.1% | -24.3% | -45.3% | -50.7% | -42.3% | -26.9% | |
| P/B Ratio | 1.45 | 1.91 | 1.43 | 1.47 | 0.98 | 0.92 | 1.03 | 1.45 | 1.57 | 2.03 | 1.79 | 1.79 | 1.56 | 1.01 | 1.39 | 1.52 | 1.52 | 1.22 | 1.14 | 1.27 | 1.80 |
| — | +107.2% | +39.1% | +1.2% | -37.6% | -54.5% | -42.4% | -19.1% | +0.6% | +101.2% | +28.3% | +18.1% | +3.0% | -17.4% | +22.7% | +19.3% | -15.8% | -43.2% | -48.6% | -40.3% | -24.0% | |
| P/FCF | 84.85 | 9.80 | — | — | 8.83 | 6.80 | — | — | 220.28 | 28.50 | — | — | 46.15 | 11.87 | — | — | — | 85.35 | 70.75 | — | 38.66 |
| — | +44.1% | — | — | -96.0% | -76.1% | — | — | +377.3% | +140.1% | — | — | — | -86.1% | — | — | — | -57.4% | -11.6% | — | -48.8% | |
| EV / EBITDA | 100.30 | — | 10.17 | — | 13.97 | — | — | — | 1.79 | — | 343.88 | — | — | — | — | — | — | — | 202.04 | 1164.23 | — |
| — | — | — | — | +678.7% | — | — | — | — | — | — | — | — | — | — | — | — | — | +1738.2% | +4198.1% | — | |
| EV / EBIT | — | — | 13.42 | — | 35.91 | — | — | — | 2.15 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | +1569.8% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 56.6% | 61.6% | 65.1% | 64.2% | 62.6% | 56.0% | 50.9% | 56.1% | -1749.2% | 3.7% | 66.7% | 60.8% | 61.3% | 60.2% | 65.4% | 60.2% | 60.9% | 56.6% | 62.7% | 59.4% | 50.6% |
| — | +9.9% | +28.0% | +14.3% | +103.6% | +1407.7% | -23.7% | -7.7% | -2954.9% | -93.8% | +2.0% | +0.9% | +0.6% | +6.3% | +4.3% | +1.4% | +20.3% | -2.8% | +14.9% | -2.8% | -1.2% | |
| Operating Margin | -9.8% | -2.3% | 9.1% | -18.5% | 2.1% | -11.6% | -14.8% | -16.4% | -2156.4% | -72.3% | -5.9% | -12.5% | -148.4% | -18.5% | -8.2% | -33.1% | -16.8% | -14.4% | -8.5% | -9.7% | -25.5% |
| — | +80.0% | +161.2% | -13.2% | +100.1% | +83.9% | -151.4% | -31.0% | -1352.8% | -290.6% | +28.1% | +62.3% | -782.1% | -28.5% | +3.9% | -241.7% | +33.9% | -537.9% | -135.4% | -364.0% | +53.6% | |
| Net Margin | -9.6% | -1.0% | 10.1% | -17.1% | 1.0% | -8.4% | -14.1% | -18.6% | 1695.0% | -77.2% | -0.3% | -11.1% | -146.6% | -15.9% | -6.2% | -27.3% | -12.4% | -10.4% | -7.2% | -8.0% | -16.2% |
| — | +87.9% | +172.1% | +8.3% | -99.9% | +89.2% | -4812.2% | -67.2% | +1256.1% | -386.8% | +95.4% | +59.2% | -1083.6% | -52.9% | +13.7% | -241.4% | +23.4% | -834.7% | -141.9% | -196.6% | +66.2% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -7.3% | -0.2% | 2.4% | -3.6% | 0.2% | -1.6% | -2.7% | -3.2% | -13.1% | -15.3% | -0.0% | -2.1% | -26.1% | -2.4% | -1.0% | -3.7% | -1.7% | -1.5% | -1.0% | -1.0% | -2.0% |
| — | +85.7% | +191.0% | -13.1% | +101.5% | +89.7% | -6285.2% | -50.2% | +49.8% | -534.9% | +95.8% | +41.6% | -1416.9% | -65.2% | +0.0% | -259.0% | +14.3% | -855.6% | -142.9% | -199.1% | +64.3% | |
| ROA | -5.5% | -0.2% | 1.8% | -2.7% | 0.2% | -1.2% | -2.1% | -2.5% | -10.1% | -12.1% | -0.0% | -1.7% | -21.0% | -2.0% | -0.8% | -3.0% | -1.4% | -1.2% | -0.8% | -0.9% | -1.7% |
| — | +86.5% | +186.9% | -10.4% | +101.5% | +89.8% | -6184.1% | -46.7% | +52.1% | -505.0% | +95.9% | +43.8% | -1393.9% | -68.3% | -0.5% | -253.7% | +14.8% | -863.1% | -145.3% | -209.1% | +58.7% | |
| ROIC | -7.0% | -0.4% | 1.8% | -3.6% | 0.4% | -2.1% | -2.6% | -2.6% | 15.5% | -13.1% | -0.8% | -2.2% | -23.9% | -2.5% | -1.2% | -4.1% | -2.2% | -1.9% | -1.1% | -1.2% | -3.2% |
| — | +78.6% | +170.4% | -35.8% | -97.2% | +84.1% | -231.1% | -17.4% | +164.8% | -432.8% | +32.3% | +45.6% | -995.2% | -28.6% | -1.7% | -231.0% | +30.8% | -523.3% | -134.6% | -365.2% | +50.0% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.18 | 0.18 | 0.17 | 0.19 | 0.18 | 0.17 | 0.17 | 0.17 | 0.17 | 0.15 | 0.13 | 0.14 | 0.13 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.07 | 0.07 |
| — | +7.0% | +0.4% | +12.1% | +8.6% | +9.1% | +26.8% | +25.5% | +28.9% | +41.3% | +22.5% | +24.7% | +20.8% | -0.7% | -1.3% | +52.8% | +48.2% | +49.5% | +46.6% | -10.7% | -11.5% | |
| Debt / EBITDA | — | — | 5.23 | — | 13.36 | — | — | — | 0.88 | — | 113.21 | — | — | — | — | — | — | — | 96.36 | 324.92 | — |
| — | — | — | — | +1427.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | +5557.0% | +6882.2% | — | |
| Current Ratio | 4.72 | 3.86 | 4.48 | 4.46 | 4.72 | 5.32 | 6.18 | 5.73 | 4.88 | 5.34 | 5.93 | 5.59 | 5.26 | 5.59 | 6.49 | 5.59 | 6.07 | 6.37 | 5.70 | 6.12 | 5.66 |
| — | -27.5% | -27.5% | -22.1% | -3.3% | -0.3% | +4.1% | +2.5% | -7.3% | -4.4% | -8.6% | -0.0% | -13.4% | -12.2% | +13.8% | -8.8% | +7.4% | +10.5% | +32.7% | +65.8% | +17.6% | |
| Quick Ratio | 3.86 | 2.72 | 3.19 | 3.37 | 3.86 | 4.47 | 5.12 | 4.53 | 3.85 | 3.78 | 3.96 | 3.85 | 4.47 | 4.03 | 4.67 | 4.15 | 4.65 | 4.95 | 4.50 | 4.82 | 4.45 |
| — | -39.1% | -37.8% | -25.6% | +0.1% | +18.1% | +29.3% | +17.8% | -13.8% | -6.1% | -15.2% | -7.2% | -3.8% | -18.7% | +3.8% | -13.9% | +4.5% | +9.0% | +38.1% | +73.1% | +25.0% | |
| Interest Coverage | — | -1.83 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -23.08 | -176.55 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ANIK stock.
Anika Therapeutics, Inc.'s current P/E is -110.3x. The average P/E over the last 2 quarters is 68.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Anika Therapeutics, Inc.'s current operating margin is -9.8%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Anika Therapeutics, Inc.'s business trajectory between earnings reports.